English
简体中文
Total: £ 56.28
Published Date: 2024-07-18 | Pages: 108 | Tables: 132 | Medical Care
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Market Analysis and Insights: Global RNAi for Therapeutic Market
The global RNAi for Therapeutic market is projected to grow from US$ 258.3 million in 2024 to US$ 2218 million by 2030, at a Compound Annual Growth Rate (CAGR) of 43.1% during the forecast period.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
Report Covers:
This report presents an overview of global market for RNAi for Therapeutic market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of RNAi for Therapeutic, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for RNAi for Therapeutic, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the RNAi for Therapeutic revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global RNAi for Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for RNAi for Therapeutic revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Segment by Type
siRNA
miRNA
shRNA
Segment by Application
Cancer
Cardiovascular
HBV
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of RNAi for Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNAi for Therapeutic companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNAi for Therapeutic revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNAi for Therapeutic Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.3 Market by Application
1.3.1 Global RNAi for Therapeutic Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Cardiovascular
1.3.4 HBV
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNAi for Therapeutic Market Perspective (2019-2030)
2.2 Global RNAi for Therapeutic Growth Trends by Region
2.2.1 RNAi for Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 RNAi for Therapeutic Historic Market Size by Region (2019-2024)
2.2.3 RNAi for Therapeutic Forecasted Market Size by Region (2025-2030)
2.3 RNAi for Therapeutic Market Dynamics
2.3.1 RNAi for Therapeutic Industry Trends
2.3.2 RNAi for Therapeutic Market Drivers
2.3.3 RNAi for Therapeutic Market Challenges
2.3.4 RNAi for Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue RNAi for Therapeutic by Players
3.1.1 Global RNAi for Therapeutic Revenue by Players (2019-2024)
3.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2019-2024)
3.2 Global RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of RNAi for Therapeutic, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global RNAi for Therapeutic Market Concentration Ratio
3.4.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2023
3.5 Global Key Players of RNAi for Therapeutic Head office and Area Served
3.6 Global Key Players of RNAi for Therapeutic, Product and Application
3.7 Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 RNAi for Therapeutic Breakdown Data by Type
4.1 Global RNAi for Therapeutic Historic Market Size by Type (2019-2024)
4.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2025-2030)
5 RNAi for Therapeutic Breakdown Data by Application
5.1 Global RNAi for Therapeutic Historic Market Size by Application (2019-2024)
5.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America RNAi for Therapeutic Market Size (2019-2030)
6.2 North America RNAi for Therapeutic Market Size by Type
6.2.1 North America RNAi for Therapeutic Market Size by Type (2019-2024)
6.2.2 North America RNAi for Therapeutic Market Size by Type (2025-2030)
6.2.3 North America RNAi for Therapeutic Market Share by Type (2019-2030)
6.3 North America RNAi for Therapeutic Market Size by Application
6.3.1 North America RNAi for Therapeutic Market Size by Application (2019-2024)
6.3.2 North America RNAi for Therapeutic Market Size by Application (2025-2030)
6.3.3 North America RNAi for Therapeutic Market Share by Application (2019-2030)
6.4 North America RNAi for Therapeutic Market Size by Country
6.4.1 North America RNAi for Therapeutic Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America RNAi for Therapeutic Market Size by Country (2019-2024)
6.4.3 North America RNAi for Therapeutic Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe RNAi for Therapeutic Market Size (2019-2030)
7.2 Europe RNAi for Therapeutic Market Size by Type
7.2.1 Europe RNAi for Therapeutic Market Size by Type (2019-2024)
7.2.2 Europe RNAi for Therapeutic Market Size by Type (2025-2030)
7.2.3 Europe RNAi for Therapeutic Market Share by Type (2019-2030)
7.3 Europe RNAi for Therapeutic Market Size by Application
7.3.1 Europe RNAi for Therapeutic Market Size by Application (2019-2024)
7.3.2 Europe RNAi for Therapeutic Market Size by Application (2025-2030)
7.3.3 Europe RNAi for Therapeutic Market Share by Application (2019-2030)
7.4 Europe RNAi for Therapeutic Market Size by Country
7.4.1 Europe RNAi for Therapeutic Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe RNAi for Therapeutic Market Size by Country (2019-2024)
7.4.3 Europe RNAi for Therapeutic Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China RNAi for Therapeutic Market Size (2019-2030)
8.2 China RNAi for Therapeutic Market Size by Type
8.2.1 China RNAi for Therapeutic Market Size by Type (2019-2024)
8.2.2 China RNAi for Therapeutic Market Size by Type (2025-2030)
8.2.3 China RNAi for Therapeutic Market Share by Type (2019-2030)
8.3 China RNAi for Therapeutic Market Size by Application
8.3.1 China RNAi for Therapeutic Market Size by Application (2019-2024)
8.3.2 China RNAi for Therapeutic Market Size by Application (2025-2030)
8.3.3 China RNAi for Therapeutic Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia RNAi for Therapeutic Market Size (2019-2030)
9.2 Asia RNAi for Therapeutic Market Size by Type
9.2.1 Asia RNAi for Therapeutic Market Size by Type (2019-2024)
9.2.2 Asia RNAi for Therapeutic Market Size by Type (2025-2030)
9.2.3 Asia RNAi for Therapeutic Market Share by Type (2019-2030)
9.3 Asia RNAi for Therapeutic Market Size by Application
9.3.1 Asia RNAi for Therapeutic Market Size by Application (2019-2024)
9.3.2 Asia RNAi for Therapeutic Market Size by Application (2025-2030)
9.3.3 Asia RNAi for Therapeutic Market Share by Application (2019-2030)
9.4 Asia RNAi for Therapeutic Market Size by Region
9.4.1 Asia RNAi for Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia RNAi for Therapeutic Market Size by Region (2019-2024)
9.4.3 Asia RNAi for Therapeutic Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Type
10.2.1 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America RNAi for Therapeutic Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Application
10.3.1 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America RNAi for Therapeutic Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Country
10.4.1 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Details
11.1.2 Alnylam Pharmaceuticals Business Overview
11.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction
11.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024)
11.1.5 Alnylam Pharmaceuticals Recent Developments
11.2 Arbutus Biopharma (Tekmira)
11.2.1 Arbutus Biopharma (Tekmira) Company Details
11.2.2 Arbutus Biopharma (Tekmira) Business Overview
11.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Introduction
11.2.4 Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2019-2024)
11.2.5 Arbutus Biopharma (Tekmira) Recent Developments
11.3 Arrowhead
11.3.1 Arrowhead Company Details
11.3.2 Arrowhead Business Overview
11.3.3 Arrowhead RNAi for Therapeutic Introduction
11.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2019-2024)
11.3.5 Arrowhead Recent Developments
11.4 Dicerna Pharmaceuticals
11.4.1 Dicerna Pharmaceuticals Company Details
11.4.2 Dicerna Pharmaceuticals Business Overview
11.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Introduction
11.4.4 Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024)
11.4.5 Dicerna Pharmaceuticals Recent Developments
11.5 Mirna Therapeutics
11.5.1 Mirna Therapeutics Company Details
11.5.2 Mirna Therapeutics Business Overview
11.5.3 Mirna Therapeutics RNAi for Therapeutic Introduction
11.5.4 Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2019-2024)
11.5.5 Mirna Therapeutics Recent Developments
11.6 Quark Pharmaceuticals
11.6.1 Quark Pharmaceuticals Company Details
11.6.2 Quark Pharmaceuticals Business Overview
11.6.3 Quark Pharmaceuticals RNAi for Therapeutic Introduction
11.6.4 Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024)
11.6.5 Quark Pharmaceuticals Recent Developments
11.7 RXi Pharmaceuticals
11.7.1 RXi Pharmaceuticals Company Details
11.7.2 RXi Pharmaceuticals Business Overview
11.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction
11.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024)
11.7.5 RXi Pharmaceuticals Recent Developments
11.8 Silence Therapeutics
11.8.1 Silence Therapeutics Company Details
11.8.2 Silence Therapeutics Business Overview
11.8.3 Silence Therapeutics RNAi for Therapeutic Introduction
11.8.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2019-2024)
11.8.5 Silence Therapeutics Recent Developments
11.9 Benitec Biopharma
11.9.1 Benitec Biopharma Company Details
11.9.2 Benitec Biopharma Business Overview
11.9.3 Benitec Biopharma RNAi for Therapeutic Introduction
11.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2019-2024)
11.9.5 Benitec Biopharma Recent Developments
11.10 miRagen Therapeutics
11.10.1 miRagen Therapeutics Company Details
11.10.2 miRagen Therapeutics Business Overview
11.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction
11.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2019-2024)
11.10.5 miRagen Therapeutics Recent Developments
11.11 Sylentis
11.11.1 Sylentis Company Details
11.11.2 Sylentis Business Overview
11.11.3 Sylentis RNAi for Therapeutic Introduction
11.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2019-2024)
11.11.5 Sylentis Recent Developments
11.12 Gradalis
11.12.1 Gradalis Company Details
11.12.2 Gradalis Business Overview
11.12.3 Gradalis RNAi for Therapeutic Introduction
11.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2019-2024)
11.12.5 Gradalis Recent Developments
11.13 Sirnaomics
11.13.1 Sirnaomics Company Details
11.13.2 Sirnaomics Business Overview
11.13.3 Sirnaomics RNAi for Therapeutic Introduction
11.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2019-2024)
11.13.5 Sirnaomics Recent Developments
11.14 Silenseed
11.14.1 Silenseed Company Details
11.14.2 Silenseed Business Overview
11.14.3 Silenseed RNAi for Therapeutic Introduction
11.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2019-2024)
11.14.5 Silenseed Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of siRNA
Table 3. Key Players of miRNA
Table 4. Key Players of shRNA
Table 5. Global RNAi for Therapeutic Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 6. Global RNAi for Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global RNAi for Therapeutic Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global RNAi for Therapeutic Market Share by Region (2019-2024)
Table 9. Global RNAi for Therapeutic Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global RNAi for Therapeutic Market Share by Region (2025-2030)
Table 11. RNAi for Therapeutic Market Trends
Table 12. RNAi for Therapeutic Market Drivers
Table 13. RNAi for Therapeutic Market Challenges
Table 14. RNAi for Therapeutic Market Restraints
Table 15. Global RNAi for Therapeutic Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global RNAi for Therapeutic Revenue Share by Players (2019-2024)
Table 17. Global Top RNAi for Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2023)
Table 18. Global RNAi for Therapeutic Industry Ranking 2022 VS 2023 VS 2024
Table 19. Global 5 Largest Players Market Share by RNAi for Therapeutic Revenue (CR5 and HHI) & (2019-2024)
Table 20. Global Key Players of RNAi for Therapeutic, Headquarters and Area Served
Table 21. Global Key Players of RNAi for Therapeutic, Product and Application
Table 22. Global Key Players of RNAi for Therapeutic, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global RNAi for Therapeutic Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global RNAi for Therapeutic Revenue Market Share by Type (2019-2024)
Table 26. Global RNAi for Therapeutic Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global RNAi for Therapeutic Revenue Market Share by Type (2025-2030)
Table 28. Global RNAi for Therapeutic Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global RNAi for Therapeutic Revenue Share by Application (2019-2024)
Table 30. Global RNAi for Therapeutic Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global RNAi for Therapeutic Revenue Share by Application (2025-2030)
Table 32. North America RNAi for Therapeutic Market Size by Type (2019-2024) & (US$ Million)
Table 33. North America RNAi for Therapeutic Market Size by Type (2025-2030) & (US$ Million)
Table 34. North America RNAi for Therapeutic Market Size by Application (2019-2024) & (US$ Million)
Table 35. North America RNAi for Therapeutic Market Size by Application (2025-2030) & (US$ Million)
Table 36. North America RNAi for Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America RNAi for Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America RNAi for Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe RNAi for Therapeutic Market Size by Type (2019-2024) & (US$ Million)
Table 40. Europe RNAi for Therapeutic Market Size by Type (2025-2030) & (US$ Million)
Table 41. Europe RNAi for Therapeutic Market Size by Application (2019-2024) & (US$ Million)
Table 42. Europe RNAi for Therapeutic Market Size by Application (2025-2030) & (US$ Million)
Table 43. Europe RNAi for Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Europe RNAi for Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 45. Europe RNAi for Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 46. China RNAi for Therapeutic Market Size by Type (2019-2024) & (US$ Million)
Table 47. China RNAi for Therapeutic Market Size by Type (2025-2030) & (US$ Million)
Table 48. China RNAi for Therapeutic Market Size by Application (2019-2024) & (US$ Million)
Table 49. China RNAi for Therapeutic Market Size by Application (2025-2030) & (US$ Million)
Table 50. Asia RNAi for Therapeutic Market Size by Type (2019-2024) & (US$ Million)
Table 51. Asia RNAi for Therapeutic Market Size by Type (2025-2030) & (US$ Million)
Table 52. Asia RNAi for Therapeutic Market Size by Application (2019-2024) & (US$ Million)
Table 53. Asia RNAi for Therapeutic Market Size by Application (2025-2030) & (US$ Million)
Table 54. Asia RNAi for Therapeutic Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 55. Asia RNAi for Therapeutic Market Size by Region (2019-2024) & (US$ Million)
Table 56. Asia RNAi for Therapeutic Market Size by Region (2025-2030) & (US$ Million)
Table 57. Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Type (2019-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Type (2025-2030) & (US$ Million)
Table 59. Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Application (2019-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Application (2025-2030) & (US$ Million)
Table 61. Middle East, Africa, and Latin America RNAi for Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 62. Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America RNAi for Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 64. Alnylam Pharmaceuticals Company Details
Table 65. Alnylam Pharmaceuticals Business Overview
Table 66. Alnylam Pharmaceuticals RNAi for Therapeutic Product
Table 67. Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 68. Alnylam Pharmaceuticals Recent Developments
Table 69. Arbutus Biopharma (Tekmira) Company Details
Table 70. Arbutus Biopharma (Tekmira) Business Overview
Table 71. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product
Table 72. Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 73. Arbutus Biopharma (Tekmira) Recent Developments
Table 74. Arrowhead Company Details
Table 75. Arrowhead Business Overview
Table 76. Arrowhead RNAi for Therapeutic Product
Table 77. Arrowhead Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 78. Arrowhead Recent Developments
Table 79. Dicerna Pharmaceuticals Company Details
Table 80. Dicerna Pharmaceuticals Business Overview
Table 81. Dicerna Pharmaceuticals RNAi for Therapeutic Product
Table 82. Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 83. Dicerna Pharmaceuticals Recent Developments
Table 84. Mirna Therapeutics Company Details
Table 85. Mirna Therapeutics Business Overview
Table 86. Mirna Therapeutics RNAi for Therapeutic Product
Table 87. Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 88. Mirna Therapeutics Recent Developments
Table 89. Quark Pharmaceuticals Company Details
Table 90. Quark Pharmaceuticals Business Overview
Table 91. Quark Pharmaceuticals RNAi for Therapeutic Product
Table 92. Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 93. Quark Pharmaceuticals Recent Developments
Table 94. RXi Pharmaceuticals Company Details
Table 95. RXi Pharmaceuticals Business Overview
Table 96. RXi Pharmaceuticals RNAi for Therapeutic Product
Table 97. RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 98. RXi Pharmaceuticals Recent Developments
Table 99. Silence Therapeutics Company Details
Table 100. Silence Therapeutics Business Overview
Table 101. Silence Therapeutics RNAi for Therapeutic Product
Table 102. Silence Therapeutics Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 103. Silence Therapeutics Recent Developments
Table 104. Benitec Biopharma Company Details
Table 105. Benitec Biopharma Business Overview
Table 106. Benitec Biopharma RNAi for Therapeutic Product
Table 107. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 108. Benitec Biopharma Recent Developments
Table 109. miRagen Therapeutics Company Details
Table 110. miRagen Therapeutics Business Overview
Table 111. miRagen Therapeutics RNAi for Therapeutic Product
Table 112. miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 113. miRagen Therapeutics Recent Developments
Table 114. Sylentis Company Details
Table 115. Sylentis Business Overview
Table 116. Sylentis RNAi for Therapeutic Product
Table 117. Sylentis Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 118. Sylentis Recent Developments
Table 119. Gradalis Company Details
Table 120. Gradalis Business Overview
Table 121. Gradalis RNAi for Therapeutic Product
Table 122. Gradalis Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 123. Gradalis Recent Developments
Table 124. Sirnaomics Company Details
Table 125. Sirnaomics Business Overview
Table 126. Sirnaomics RNAi for Therapeutic Product
Table 127. Sirnaomics Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 128. Sirnaomics Recent Developments
Table 129. Silenseed Company Details
Table 130. Silenseed Business Overview
Table 131. Silenseed RNAi for Therapeutic Product
Table 132. Silenseed Revenue in RNAi for Therapeutic Business (2019-2024) & (US$ Million)
Table 133. Silenseed Recent Developments
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Global RNAi for Therapeutic Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global RNAi for Therapeutic Market Share by Type: 2023 VS 2030
Figure 3. siRNA Features
Figure 4. miRNA Features
Figure 5. shRNA Features
Figure 6. Global RNAi for Therapeutic Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 7. Global RNAi for Therapeutic Market Share by Application: 2023 VS 2030
Figure 8. Cancer Case Studies
Figure 9. Cardiovascular Case Studies
Figure 10. HBV Case Studies
Figure 11. Others Case Studies
Figure 12. RNAi for Therapeutic Report Years Considered
Figure 13. Global RNAi for Therapeutic Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global RNAi for Therapeutic Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global RNAi for Therapeutic Market Share by Region: 2023 VS 2030
Figure 16. Global RNAi for Therapeutic Market Share by Players in 2023
Figure 17. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by RNAi for Therapeutic Revenue in 2023
Figure 19. North America RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America RNAi for Therapeutic Market Share by Type (2019-2030)
Figure 21. North America RNAi for Therapeutic Market Share by Application (2019-2030)
Figure 22. North America RNAi for Therapeutic Market Share by Country (2019-2030)
Figure 23. United States RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe RNAi for Therapeutic Market Size YoY (2019-2030) & (US$ Million)
Figure 26. Europe RNAi for Therapeutic Market Share by Type (2019-2030)
Figure 27. Europe RNAi for Therapeutic Market Share by Application (2019-2030)
Figure 28. Europe RNAi for Therapeutic Market Share by Country (2019-2030)
Figure 29. Germany RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. China RNAi for Therapeutic Market Size YoY (2019-2030) & (US$ Million)
Figure 36. China RNAi for Therapeutic Market Share by Type (2019-2030)
Figure 37. China RNAi for Therapeutic Market Share by Application (2019-2030)
Figure 38. Asia RNAi for Therapeutic Market Size YoY (2019-2030) & (US$ Million)
Figure 39. Asia RNAi for Therapeutic Market Share by Type (2019-2030)
Figure 40. Asia RNAi for Therapeutic Market Share by Application (2019-2030)
Figure 41. Asia RNAi for Therapeutic Market Share by Region (2019-2030)
Figure 42. Japan RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. South Korea RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. China Taiwan RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Southeast Asia RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. India RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Australia RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America RNAi for Therapeutic Market Size YoY (2019-2030) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America RNAi for Therapeutic Market Share by Type (2019-2030)
Figure 50. Middle East, Africa, and Latin America RNAi for Therapeutic Market Share by Application (2019-2030)
Figure 51. Middle East, Africa, and Latin America RNAi for Therapeutic Market Share by Country (2019-2030)
Figure 52. Brazil RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Mexico RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Turkey RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. Saudi Arabia RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. Israel RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 57. GCC Countries RNAi for Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 58. Alnylam Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 59. Arbutus Biopharma (Tekmira) Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 60. Arrowhead Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 61. Dicerna Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 62. Mirna Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 63. Quark Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 64. RXi Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 65. Silence Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 66. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 67. miRagen Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 68. Sylentis Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 69. Gradalis Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 70. Sirnaomics Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 71. Silenseed Revenue Growth Rate in RNAi for Therapeutic Business (2019-2024)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
